Alnylam Pharma (ALNY) Appoints Elliott Sigal to its Board
- Wall St ends lower as investors weigh fresh employment data
- U.S. private employers add 103,000 jobs in November - ADP
- Data storage group MongoDB delivers upbeat guidance after Q3 results top estimates
- Stocks edge up, 10-year Treasury yield falls as rate cut timing weighed
- A major Wall Street bank is out with S&P 500 forecast for 2024
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades of senior leadership and board experience at biopharmaceutical companies. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb (BMS) and as a director on the company’s board. During his tenure at BMS, he was instrumental in building the company’s leading research position in immuno-oncology. Under his leadership, 14 new medicines came to market in multiple therapeutic areas including cardiometabolic disease, infectious disease, inflammatory disease, neuroscience and oncology.
“We are thrilled to welcome Elliott to our Board at an especially important and exciting time in our Company’s history. As a deeply accomplished leader, Elliott will bring valuable experience to Alnylam and our Board as we continue to advance our RNAi therapeutics to transform the lives of patients afflicted with rare and prevalent diseases with unmet need,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “We look forward to his contributions in the years ahead.”
“Alnylam has revolutionized RNAi as a new class of medicines that improve patients’ lives,” said Dr. Sigal. “I am excited to join the Company at this critical inflection point and to work with the Board and management as we continue to grow the company’s commercial portfolio and advance its RNAi therapeutic pipeline.”
Dr. Sigal currently serves as co-chair of the Scientific Advisory Board for Amgen, Inc. and as a senior advisor to the healthcare team of New Enterprise Associates. He is a member of the Board of Directors for the public biotechnology companies Adaptimmune Therapeutics plc, Vir Biotechnology, Inc. and Surface Oncology, Inc., as well as the private companies Tessera Therapeutics and Affinia Therapeutics Inc. Prior Board positions include Spark Therapeutics, Inc. from 2014 to 2019, Mead Johnson Nutrition from 2009 to 2017 and BMS from 2011 to 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exelon Corp. (EXC) Appoints Bryan Segedi to Board of Directors
- Alnylam to Webcast Virtual R&D Day
- AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
Create E-mail Alert Related CategoriesBoard Changes, Corporate News
Related EntitiesNew Enterprise Associates, Twitter
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!